BBNX

Beta Bionics, Inc. Common Stock

$12.80 +5.61%

Recent alerts on BBNX

All signals →

Insider trade Sale by Lezack Adam

Insider trade Sale by Jones Christy

SEC filing BBNX Elects Sean Carney, Christy Jones as Directors, Ratifies Ernst & Young LLP Appointment with 99.9% and 99.8% Approval Respectively

News Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

News Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5%

SEC filing BBNX Reports $27.6M Q1 Revenue, $21.9M Net Loss, Raises FY2026 Guidance to $131-136M, 37-39% PBP Reimbursement

Insider trade Sale by Mark Hopman (Chief Commercial Officer)

Insider trade Sale by Steven Jon Russell (Chief Medical Officer)

Insider trade Sale by Mark Hopman (Chief Commercial Officer)

Insider trade Sale by Mark Hopman (Chief Commercial Officer)

Insider trade Sale by Steven Jon Russell (Chief Medical Officer)

Insider trade Sale by Mike Mensinger (Chief Product Officer)

Insider trade Sale by Stephen Feider (Chief Financial Officer)

Insider trade Sale by Sean Saint (President & CEO)

News Beta Bionics outlines $130M–$135M 2026 revenue target while expanding sales force and pharmacy channel

SEC filing BBNX Reports $100.3M Revenue, $13.5M Net Loss, $264.7M Cash, $130M-$135M 2026 Guidance

Short volume Short volume 79% of volume (6.7σ)

News Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX

News Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX

News BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

Short interest Short Interest

Scanner Unusual volume (z=2.8)

Get push alerts for BBNX

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS